Jun 2026 (Q2 FY26) — Aug 6, 2026
Novavax Q2 FY26 — Strong Partner Momentum and Pipeline Progress
Read the full callNovavax (NVAX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Novavax earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 56.7 | −76.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -96.8 | −139.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -53.4 | −150.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$10.82 −3.91% · −$0.44
Performance +33.6% 1Y
1Y: $8.1 on 17 Oct 2025 → $10.82. High $12.82 (13 Oct 2026), low $6.22 (20 Nov 2025).
- Previous close
- $11.26
- 52-week range
- $6.22 – $12.82
- One year
- +23.09%
Overview
- Symbol
- NVAX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Novavax earnings calls (NVAX)
Financials
What the filings say
Net profit, year on year: −150% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 85 | 88 | 667 | 239 | 70 | 147 | 140 | 57 |
| Expenses | 219 | 219 | 151 | 138 | 248 | 133 | 155 | 112 |
| Operating profit | -134 | -131 | 516 | 101 | -178 | 14 | -15 | -55 |
| Operating margin | −158.6% | −148.4% | 77.3% | 42.3% | −252.7% | 9.7% | −11.1% | −96.8% |
| Interest | 4 | 8 | 6 | 6 | 5 | 6 | 5 | 6 |
| Profit before tax | -122 | -74 | 520 | 107 | -203 | 18 | -9 | -52 |
| Tax rate | 0.8% | −10.1% | 0.2% | 0.9% | 0.3% | 2.1% | −11.6% | −3.3% |
| Net profit | -121 | -81 | 519 | 107 | -202 | 18 | -9 | -53 |
| EPS ($ per share) | -0.76 | — | 3.22 | 0.66 | -1.25 | — | -0.06 | -0.32 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Reserves | -1,299 | -1,432 | -1,874 | -3,618 | -4,276 | -4,821 | -5,008 | -4,568 |
| Total liabilities | 376 | 359 | 955 | 2,928 | 2,893 | 2,514 | 2,184 | 1,304 |
| Fixed assets | 28 | 11 | 180 | 226 | 294 | 306 | 138 | 45 |
| Investments | 22 | 0 | 158 | 0 | — | 0 | 393 | 494 |
| Total assets | 208 | 173 | 1,582 | 2,577 | 2,259 | 1,797 | 1,560 | 1,177 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -185 | -137 | -43 | 323 | -416 | -714 | -87 | -245 |
| Cash from investing | 29 | 38 | -378 | 100 | -93 | -59 | -204 | -78 |
| Cash from financing | 103 | 98 | 985 | 462 | 325 | 4 | 261 | 28 |
| Net cash flow | -53 | 0 | 567 | 880 | -179 | -765 | -39 | -289 |
| Capital expenditure | -1 | -2 | -109 | -112 | -89 | -54 | -13 | -6 |
| Free cash flow | -186 | -138 | -152 | 211 | -505 | -768 | -100 | -250 |
Insider filings
37 filings between Oct 29, 2025 and Jun 20, 2026.
Open market
decisions to buy or sellNobody bought or sold NVAX on the open market in this window. The filings below are 23 option exercises and 14 tax withholdings.
Compensation
not trading decisions- 23
- Option exercise — converted options into shares
- 14
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 20, 2026 | MOTT DAVID M Director | Option exercise | 18,880 | — |
| Jun 20, 2026 | Alton Gregg H Director | Option exercise | 18,880 | — |
| Jun 20, 2026 | MCGLYNN MARGARET G Director | Option exercise | 18,880 | — |
| Jun 20, 2026 | DOUGLAS RICHARD Director | Option exercise | 18,880 | — |
| Jun 20, 2026 | King Rachel K. Director | Option exercise | 18,880 | — |
| Jun 20, 2026 | Rodgers Richard J Director | Option exercise | 18,880 | — |
| Apr 25, 2026 | Newton Charles W. Director | Option exercise | 9,520 | $0 |
| Mar 10, 2026 | Shiver John W. Director | Option exercise | 7,947 | $0 |
| Mar 7, 2026 | Kelly James Patrick EVP, CFO and Treasurer | Option exercise | 12,223 | $0 |
| Mar 7, 2026 | Kelly James Patrick EVP, CFO and Treasurer | Tax withheld | 5,904 | $58.9K |
| Mar 3, 2026 | Draghia-Akli Ruxandra EVP, Research & Development | Option exercise | 26,667 | $0 |
| Mar 3, 2026 | Draghia-Akli Ruxandra EVP, Research & Development | Tax withheld | 11,313 | $107.4K |
| Mar 3, 2026 | Casey Mark J EVP, Chief Legal Officer | Option exercise | 37,500 | $0 |
| Mar 3, 2026 | Casey Mark J EVP, Chief Legal Officer | Tax withheld | 11,378 | $108.0K |
| Mar 3, 2026 | O'Hara Elaine EVP, Chief Strategy Officer | Option exercise | 56,334 | $0 |
| Mar 3, 2026 | O'Hara Elaine EVP, Chief Strategy Officer | Tax withheld | 22,429 | $212.9K |
| Mar 3, 2026 | Jacobs John C President and CEO | Option exercise | 150,167 | $0 |
| Mar 3, 2026 | Jacobs John C President and CEO | Tax withheld | 69,288 | $657.5K |
| Mar 3, 2026 | Kelly James Patrick EVP, CFO and Treasurer | Option exercise | 43,167 | $0 |
| Mar 3, 2026 | Kelly James Patrick EVP, CFO and Treasurer | Tax withheld | 20,850 | $197.9K |
| Mar 1, 2026 | Casey Mark J EVP, Chief Legal Officer | Option exercise | 4,000 | $0 |
| Mar 1, 2026 | Casey Mark J EVP, Chief Legal Officer | Tax withheld | 1,214 | $12.3K |
| Mar 1, 2026 | O'Hara Elaine EVP, Chief Strategy Officer | Option exercise | 19,600 | $0 |
| Mar 1, 2026 | O'Hara Elaine EVP, Chief Strategy Officer | Tax withheld | 5,375 | $54.5K |
| Mar 1, 2026 | O'Hara Elaine EVP, Chief Strategy Officer | Option exercise | 40,000 | $0 |
| Mar 1, 2026 | O'Hara Elaine EVP, Chief Strategy Officer | Tax withheld | 10,969 | $111.2K |
| Mar 1, 2026 | Kelly James Patrick EVP, CFO and Treasurer | Option exercise | 58,666 | $0 |
| Mar 1, 2026 | Kelly James Patrick EVP, CFO and Treasurer | Tax withheld | 28,366 | $287.6K |
| Mar 1, 2026 | Jacobs John C President and CEO | Option exercise | 83,333 | $0 |
| Mar 1, 2026 | Jacobs John C President and CEO | Tax withheld | 38,450 | $389.9K |
| Jan 23, 2026 | Jacobs John C President and CEO | Option exercise | 83,197 | $0 |
| Jan 23, 2026 | Jacobs John C President and CEO | Tax withheld | 39,132 | $358.8K |
| Dec 11, 2025 | Casey Mark J EVP, Chief Legal Officer | Option exercise | 41,899 | $0 |
| Dec 11, 2025 | Casey Mark J EVP, Chief Legal Officer | Tax withheld | 12,713 | $85.0K |
| Nov 11, 2025 | Draghia-Akli Ruxandra Section 16 | Option exercise | 14,257 | $0 |
| Nov 11, 2025 | Draghia-Akli Ruxandra Section 16 | Tax withheld | 6,048 | $44.8K |
| Oct 29, 2025 | Rodgers Richard J Director | Option exercise | 3,800 | — |
| Jun 12, 2025 | MCGLYNN MARGARET G Director | Option exercise | 10,420 | $0 |
| Jun 12, 2025 | Alton Gregg H Director | Option exercise | 10,420 | $0 |
| Jun 12, 2025 | DOUGLAS RICHARD Director | Option exercise | 10,420 | $0 |
| Jun 12, 2025 | MOTT DAVID M Director | Option exercise | 10,420 | $0 |
| Jun 12, 2025 | Rodgers Richard J Director | Option exercise | 10,420 | $0 |
| Jun 12, 2025 | King Rachel K. Director | Option exercise | 10,420 | $0 |
| Mar 7, 2025 | Kelly James Patrick EVP, CFO and Treasurer | Option exercise | 12,223 | $0 |
| Mar 7, 2025 | Trizzino John President and COO | Option exercise | 28,890 | $0 |
| Mar 7, 2025 | Trizzino John President and COO | Tax withheld | 13,954 | $116.4K |
| Mar 7, 2025 | Kelly James Patrick EVP, CFO and Treasurer | Tax withheld | 5,904 | $49.2K |
| Mar 1, 2025 | Kelly James Patrick EVP, CFO and Treasurer | Tax withheld | 28,337 | $236.0K |
| Mar 1, 2025 | Casey Mark J EVP, Chief Legal Officer | Option exercise | 4,000 | $0 |
| Mar 1, 2025 | Casey Mark J EVP, Chief Legal Officer | Tax withheld | 1,214 | $10.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for NOVAVAX INC
Free account. Everything above stays public.
Write why you follow NOVAVAX INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading